@entity632 , @entity5713 , and XXXX (CALGB 50203) for stage I/II nonbulky @entity978 : pretreatment prognostic factors and interim PET.

@entity632 @entity1 @entity137 @entity2699 @entity5 @entity1778 @entity1732 @entity978 @entity136 @entity5713
To reduce @entity632 , @entity1732 , @entity5713 and @entity2699 @entity137 , the @entity5 and @entity1778 Group B conducted a phase 2 trial of @entity632 , @entity5713 , and @entity136 for newly diagnosed, nonbulky stages I and II @entity978 . Ninety-nine assessable @entity1 received 6 cycles of @entity632 25 mg/m(2), @entity5713 6 mg/m(2), and @entity136 800 mg/m(2) (1000 mg/m(2) in first 6) on days 1 and 15 every 28 days. Computed tomography (CT) and positron emission tomography (PET) were performed before and after 2 and 6 cycles. Complete remission (CR)/CR unconfirmed was achieved in 72 of 99 @entity1 (72.7%) and partial remission in 24 of 99 @entity1 (24.2%). The CR rate was 81% when using PET criteria. Two @entity1 have died of @entity978 progression. Median follow-up for nonprogressing @entity1 is 3.3 years. The progression-free survival (PFS) at 3 years was 77% (95% confidence interval, 68%-84%). The relapse rate was less than 10% for @entity1 with favorable prognostic factors. The 2-year PFS for cycle 2 PET-negative and -positive @entity1 was 88% and 54%, respectively (P = .0009), compared with 89% and 27% for cycle 6 PET-negative and -positive @entity1 (P = .0001). Although the CR rate and PFS were lower than anticipated, @entity1 with favorable prognostic features had a low rate of relapse. Cycle 2 PET and cycle 6 PET were predictive of PFS.
